IPCIQ (IntelliPharmaCeutics International) Other Current Assets: $0.46 Mil (As of Aug. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IPCIQ IntelliPharmaCeutics International Inc IPCIQ
16 GF Score
Price $0.15
View Full Analysis

What is IntelliPharmaCeutics International Other Current Assets?

IntelliPharmaCeutics International IPCIQ -100.00% 16 Other Current Assets is $0.46 Mil as of Aug. 2023. GuruFocus rates IPCIQ with a GF Score™ of 16/100.

IntelliPharmaCeutics International's other current assets for the quarter that ended in Aug. 2023 was $0.46 Mil.

IntelliPharmaCeutics International's quarterly other current assets increased from Feb. 2023 ($0.45 Mil) to May. 2023 ($0.46 Mil) and increased from May. 2023 ($0.46 Mil) to Aug. 2023 ($0.46Mil).

IntelliPharmaCeutics International's annual other current assets declined from Nov. 2020 ($1.10 Mil) to Nov. 2021 ($0.33 Mil) increased from Nov. 2021 ($0.33 Mil) to Nov. 2022 ($0.41 Mil).


IntelliPharmaCeutics International Other Current Assets Related Terms


IntelliPharmaCeutics International Other Current Assets Historical Data

* Premium members only.

The historical data trend for IntelliPharmaCeutics International's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IntelliPharmaCeutics International Other Current Assets Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 0.93 1.10 0.33 0.41

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.41 0.45 0.46 0.46
IPCIQ
16GF Score
IntelliPharmaCeutics International Inc IPCIQ
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IntelliPharmaCeutics International Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.46 Mil mean?
IntelliPharmaCeutics International (IPCIQ) has a Other Current Assets of $0.46 Mil as of Aug. 2023. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on IntelliPharmaCeutics International.
Is IntelliPharmaCeutics International's Other Current Assets too high?
IntelliPharmaCeutics International's current Other Current Assets is $0.46 Mil. Overall, IntelliPharmaCeutics International has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does IntelliPharmaCeutics International's Other Current Assets compare to CHRO and KTTA?
IntelliPharmaCeutics International's Other Current Assets of $0.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on IntelliPharmaCeutics International. IntelliPharmaCeutics International's current Other Current Assets is $0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IntelliPharmaCeutics International stock overvalued right now?
IntelliPharmaCeutics International (IPCIQ) has a current Other Current Assets of $0.46 Mil. The current Other Current Assets is $0.46 Mil. IntelliPharmaCeutics International's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For IntelliPharmaCeutics International (IPCIQ), the current Other Current Assets is $0.46 Mil as of Aug. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IntelliPharmaCeutics International Business Description

Address 30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company's patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline.
16GF Score

Get the complete analysis for IPCIQ

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price